What changed for Liver Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Liver Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 610 to 620 (+10)
- Late-stage (Phase 3) trials 45 to 46 (+1)
- Trials on record 3,366 to 3,418 (+52)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Liver Cancer in July 2026. Voxsanity tracks 5 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 52 trials tracked for Liver Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04358185 · results posted 4 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04358185) enrolled 19 participants, all of whom received a drug called itacitinib. The trial was looking at two main things: how often participants experienced unwanted medical events (called adverse events) while taking the drug, and whether the tumours responded to treatment in people with a type of liver cancer called hepatocellular carcinoma (HCC). Fifteen of the 19 participants completed the study, and four did not. The reported data shows that 14 out of 19 participants experienced at least one adverse event consider...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03755791 · results posted 11 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03755791) enrolled 837 people across three groups: 432 received a combination of two medicines called cabozantinib and atezolizumab, 188 received cabozantinib on its own, and 217 received a medicine called sorafenib (the comparison group). The trial was measuring two main things: how long participants went without their disease getting worse (called progression-free survival, or PFS — the time from the start of treatment until scans showed the disease had grown or a new spot appeared, or the person died), and how long part...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04941287 · results posted 23 May 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 57 people across two groups. Twenty-nine participants were in Arm A, receiving a combination of three medicines (cobimetinib, atezolizumab, and varlilumab), and 28 participants were in Arm B, receiving two of those medicines (atezolizumab and varlilumab). The trial was measuring how many people's tumours shrank or disappeared, how long it took for the disease to progress, and how long participants survived overall. The reported data shows that for the primary outcome of tumour response — meaning tumours that either d...
-
NCT04340193 · results posted 26 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04340193) enrolled 26 people in total across three groups: 9 participants received a combination of nivolumab, ipilimumab, and a procedure called TACE (a treatment that delivers medicine directly to liver tumours via blood vessels); 9 received nivolumab combined with TACE; and 8 received TACE alone. The trial was primarily focused on tracking participants' safety experiences — specifically recording any unwanted medical events, serious medical events, deaths, treatment drop-outs due to side effects, and abnormal blood test...
-
NCT02649868 · results posted 11 July 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 17 participants, all of whom completed the study — none dropped out. The trial involved people with tumours in the liver who were being treated with a procedure called bead embolisation, where tiny beads are delivered through a blood vessel into the liver. The trial was measuring whether these beads — which are designed to show up on imaging — could actually be seen on a type of specialised X-ray called cone beam CT, and whether the pattern of where the beads spread in the liver matched a computer-predicted map of tha...
-
NCT03211416 · results posted 29 May 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 37 people, all of whom received a combination of two medicines — sorafenib tosylate and pembrolizumab. Twenty-seven participants completed the study, while 10 did not. The trial was primarily measuring how many participants showed a reduction in their tumour — either a partial response (tumour shrank) or a complete response (tumour could no longer be detected) — using a standardised set of criteria for assessing tumour changes. The reported data shows that 8 out of the evaluable participants had a recorded tumour res...
-
NCT01516710 · results posted 10 May 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 280 people in total — 147 assigned to open liver resection (traditional surgery with a large cut) and 133 assigned to laparoscopic liver resection (keyhole surgery using small cuts and a camera). Most participants completed the study: 143 in the open surgery group and 129 in the keyhole surgery group, with 4 people in each group not completing it. The trial was comparing the two surgical approaches across a range of measures, with the main focus being on complications occurring within the first 30 days after the opera...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02762266 · results posted 12 March 2024
According to the results reported on ClinicalTrials.gov, this trial compared two treatments for liver tumours: Transarterial Chemoembolization (TACE), a procedure that delivers chemotherapy directly to a tumour via its blood supply, and Stereotactic Body Radiation Therapy (SBRT), a type of highly targeted radiation treatment. Six people were enrolled in each group (12 in total). In the TACE group, only 4 of the 6 who started actually received treatment and completed the study, while 2 did not complete it. In the SBRT group, all 6 who started received treatment and completed the study. The rep...
-
NCT04102098 · results posted 18 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04102098) enrolled 668 people in total — 334 in an "Active Surveillance" group (meaning they were monitored without receiving the study treatment) and 334 in a group that received a combination of two medicines called atezolizumab and bevacizumab. The trial was studying people who had been treated for liver cancer (hepatocellular carcinoma) and was looking at whether adding these medicines after treatment might affect how long people remained free of the cancer coming back, and how long they lived overall. The reported da...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02795429 · results posted 3 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02795429) looked at two medicines used together — capmatinib and spartalizumab — in people with advanced cancer. The trial had two stages: a first stage (Phase Ib) to find a safe dose by testing three different dose levels of capmatinib (200 mg, 300 mg, or 400 mg twice daily), each combined with a fixed dose of spartalizumab, and a second stage (Phase II) that compared the combination at the highest dose against spartalizumab given on its own. In total, 89 people took part across all five groups — 6, 10, and 11 people in t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01730937 · results posted 3 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT01730937) enrolled 193 people with liver cancer (hepatocellular carcinoma) who also had a blood clot in a major liver vessel — a condition known as tumour thrombosis. Participants were randomly assigned to one of two groups: 97 received the drug sorafenib on its own, and 96 received a type of targeted radiation called SBRT (stereotactic body radiotherapy) followed by sorafenib. The trial's main goal was to measure how long participants lived overall, and it also tracked how quickly the cancer progressed, quality of life, a...
-
NCT03586973 · results posted 18 April 2023
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called cabozantinib (taken as a 60 mg daily dose) in two separate groups of cancer patients — Cohort A, which had 20 participants, and Cohort B, which had 14 participants. The main thing the trial was measuring was how many people in each group went at least 24 weeks without their disease getting worse or dying — this is called the "progression-free survival rate" at 24 weeks. The trial also tracked several secondary measures: how long on average participants went without their disease worsening (progression-f...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03684811 · results posted 25 January 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03684811) enrolled 93 participants across nine groups (called cohorts), testing a drug called FT-2102 in people with different types of cancer, including brain tumours and solid tumours. The cohorts received different doses or schedules of the drug. The trial was measuring two main things: how many participants experienced a serious drug-related side effect serious enough to limit the dose (called a "dose-limiting toxicity"), and how many participants' tumours showed a measurable response to the treatment. Notably, the rep...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00980460 · results posted 28 December 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 236 children across five groups based on how advanced their liver tumour (hepatoblastoma) was: a Very Low-risk group (8 children), a Low-risk group (51 children), an Intermediate-risk group (105 children), and two High-risk groups (32 and 40 children respectively). Each group received a different treatment regimen suited to their risk level. The trial was measuring how many children remained free of disease events over five years, as well as tracking serious side effects and, for some groups, how the tumour responded...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03434379 · results posted 5 November 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03434379) compared two treatment approaches for liver cancer (hepatocellular carcinoma): a combination of atezolizumab and bevacizumab versus sorafenib alone. The trial was run in two parts — a global portion, which enrolled 336 people in the combination group and 165 in the sorafenib group, and a separate China extension, which enrolled 133 and 61 people in the same respective groups. The trial measured how long participants lived overall (called overall survival), how long it took for their cancer to grow or for them to...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02423343 · results posted 9 September 2021
According to the results reported on ClinicalTrials.gov, this trial tested a combination of two drugs — galunisertib and nivolumab — in people with advanced cancers. The trial had two stages: a smaller Phase 1b stage (15 participants spread across four groups) focused on finding the right dose, and a larger Phase 2 stage that included 25 people with non-small cell lung cancer (NSCLC) and 1 person with liver cancer (hepatocellular carcinoma, or HCC). In total, 41 people started the trial and received at least one dose of the study drugs. The reported data shows that in the Phase 1b dose-findin...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03256344 · results posted 9 June 2021
According to the results reported on ClinicalTrials.gov, this trial looked at a combination of two medicines — talimogene laherparepvec (injected directly into tumours) and atezolizumab (given through a drip) — in people with two different types of cancer: triple negative breast cancer (TNBC) and colorectal cancer (CRC). A total of 36 people were enrolled across both groups — 11 with TNBC and 25 with CRC. The trial was primarily measuring whether the combination caused any serious treatment-related side effects during an early observation window, known as "dose-limiting toxicities" (DLTs) — th...
-
NCT03111732 · results posted 15 April 2021
According to the results reported on ClinicalTrials.gov, this trial looked at a combination of three medicines — pembrolizumab, oxaliplatin, and capecitabine — given together to people with a form of cancer. Eleven people entered the trial, six completed it, and five did not finish. The main thing the trial was measuring was how long participants went without their disease getting worse (called "progression-free survival"). The reported data shows that, on average (the median — meaning half of participants did better and half did worse), people went 4.54 months before their disease showed sig...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01033240 · results posted 8 April 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 163 people with advanced liver cancer. Participants were split into three groups: 55 received sorafenib alone (an existing treatment), 53 received sorafenib plus a lower dose of an investigational drug called CS-1008, and 55 received sorafenib plus a higher dose of CS-1008. The trial was primarily measuring how long it took for the cancer to progress (get worse or spread), and also looked at how long participants survived overall, how tumours responded to treatment, and what unwanted medical events occurred during the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02670122 · results posted 30 March 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 131 people who had been diagnosed with non-resectable hepatocellular carcinoma (a form of liver cancer that could not be surgically removed). Of these, 127 completed the study and 4 did not. The trial was measuring safety-related events following a procedure called DEB-TACE — a technique where tiny drug-loaded beads are delivered directly to the tumour — as well as how tumours responded to the procedure over time and how long participants lived overall. The reported data shows that, out of 131 participants, 9 experie...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02548910 · results posted 18 March 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02548910) enrolled 62 participants in total — 31 in a "Phlebotomy" group (where blood was temporarily removed before surgery) and 31 in a "Control" group (no such removal). All 62 participants completed the study. The trial was primarily looking at whether the approach was practical to run (feasibility) and at how much blood was lost during surgery, measured by tracking changes in haemoglobin (a protein in red blood cells) levels before and after the operation. The reported data shows that the 62 participants recruited me...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03006926 · results posted 31 December 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT03006926) involved 104 participants in total — 6 in an initial safety-checking phase (called the "DLT part") and 98 in a larger follow-on phase (called the "Expansion part"). All participants received a combination of two medicines: lenvatinib (either 12 mg or 8 mg daily) and pembrolizumab (200 mg). The trial was studying liver cancer (hepatocellular carcinoma) as a first-line treatment, and was measuring things like unwanted medical events that occurred during treatment, whether tumours shrank or disappeared, and how long...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02562755 · results posted 16 December 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02562755) enrolled 234 people in the Pexa-Vec followed by Sorafenib group and 225 people in the Sorafenib-alone group, for a total of 459 participants. The trial was measuring outcomes in people with liver cancer, comparing a combination approach (Pexa-Vec, a type of virus-based treatment, given first, followed by Sorafenib, a cancer medicine) against Sorafenib given on its own. The main thing the trial set out to measure was the Overall Response Rate — that is, the proportion of participants whose tumours showed a meaning...
-
NCT02966223 · results posted 25 September 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 20 people in a single group, all of whom underwent both MRI and HIDA scans (a type of imaging that looks at how well the liver is working). The trial was measuring changes in liver function before and three months after a treatment called Yttrium-90 (a form of internal radiation delivered to the liver). Specifically, it aimed to look at both regional changes (in particular areas of the liver) and global changes (across the whole liver), and to explore whether those changes were related to the dose of Yttrium-90 each p...
-
NCT01246986 · results posted 7 August 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT01246986) enrolled 204 people in total across seven groups, all of whom received at least one dose of the study drug. The trial was investigating a medicine called galunisertib (also referred to as LY2157299), given either on its own or alongside other medicines (sorafenib or ramucirumab), in people with liver cancer. The study was looking at two blood proteins — alpha-fetoprotein (AFP) and TGF-β — to see whether changes in those proteins were linked to how long participants lived overall, and also at how quickly the cance...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01755767 · results posted 15 July 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT01755767) enrolled 383 people in total with inoperable liver cancer (hepatocellular carcinoma) who had already received one prior treatment. Participants were split into four groups based on the dose of the study drug, tivantinib, or a matching placebo (a dummy treatment with no active ingredient). The main thing the trial was measuring was how long participants lived overall, specifically in those whose tumours showed high levels of a protein called MET. The reported data shows that, in the main group of interest (the 12...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02576509 · results posted 26 June 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02576509) enrolled 743 people with liver cancer (hepatocellular carcinoma) — 371 assigned to receive nivolumab (a type of immunotherapy, given at 240 mg) and 372 assigned to receive sorafenib (a standard tablet treatment, given at 400 mg). The trial was primarily measuring how long participants lived overall, and also looked at secondary measures including how many participants' tumours shrank or disappeared, and how long it was before the disease got worse. The reported data shows that, based on statistical estimates, th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01721954 · results posted 22 October 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 209 people with cancer — 105 in a group receiving a chemotherapy regimen called mFOLFOX6 combined with a procedure called SIRT (Selective Internal Radiation Therapy, a way of delivering radiation directly to liver tumours), and 104 in a group receiving mFOLFOX6 chemotherapy alone. The trial was primarily measuring how long people lived overall, and also tracking how long it was before their cancer showed signs of growing or spreading further. The reported data shows that for overall survival — the time from when some...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02200042 · results posted 28 August 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02200042) was set up to compare two approaches — radiation therapy versus observation (no radiation) — in people with a particular cancer condition. The trial aimed to measure how long participants lived overall (overall survival), as well as a range of other outcomes including whether the cancer spread to other parts of the body (distant metastases), whether it progressed locally or in nearby lymph nodes, how long people lived without the cancer getting worse (progression-free survival), and what side effects occurred. T...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02635347 · results posted 20 August 2019
According to the results reported on ClinicalTrials.gov, this trial looked at a procedure called Remote Ischemic Conditioning (RIC) in people receiving a liver transplant. RIC involves briefly restricting and then restoring blood flow to a limb (such as an arm or leg) using a blood pressure cuff, with the aim of studying its effects around the time of transplant. The trial enrolled 31 people into the RIC group and compared them to a historical control group of 63 people (meaning a separate group whose records were reviewed rather than participants recruited at the same time). The main thing th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 52 reported results for Liver Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, liver cancer currently attracts a very large amount of public research funding in the United States, and that investment has remained broadly steady from year to year. This kind of sustained, substantial commitment suggests that liver cancer is an established priority for publicly funded science, with ongoing resources directed toward better understanding and treatin...
See the full Liver Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.